GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Growth Rank

ALMS (Alumis) Growth Rank : 0 (As of Dec. 15, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alumis Growth Rank?

Alumis has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Alumis Growth Rank Related Terms

Thank you for viewing the detailed overview of Alumis's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Alumis Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.